Decent Newsroom
Sign In

Dopamine: Upregulation Without Tolerance

By Nootopics July 3, 2026

Research and education, not medical advice.

For years I have been preaching the beneficial effects of Bromantane and ALCAR, as non-addictive means to truly upregulate dopamine long-term. This page compiles what I’ve learned about psychostimulants into one reference. Bromantane and ALCAR are the best substances available for dopamine upregulation.

Why increase dopamine?

Proper dopamine function is necessary for the drive to accomplish goals. Reductively, low dopamine can be characterized by pessimism and low motivation. These conditions benefit most from higher dopamine: Narcolepsy, [1] Autoimmunity/ Chronic Fatigue Syndrome (CFS, neurasthenia [18] ) [3] Social Anxiety Disorder (SAD) [4] Low confidence, [5] Low motivation [6] Anhedonia (lack of pleasure) [7] [8] And of course Parkinson’s and ADHD [2]

The effects of stimulants vary by condition, and likewise it may vary by stimulant class. For instance a mild dopaminergic effect may benefit those with social anxiety, low confidence, low motivation and anhedonia, but a narcoleptic may not fare the same.

To put it simply, dopamine is the motivating neurotransmitter. And this bleeds into things such as optimism, confidence, social interaction, mood, learning etc.

The dopamine/CREB cascade

Here’s a simplified version of the dopamine/ CREB cascade:

Dopamine –> D1 activation –> Adenylate Cyclase –> Cyclic Adenosine Monophosphate (cAMP) production –> Protein Kinase A –> CREB (key factor in learning and memory) –> (ΔFosB –> inhibits C-Fos), Dynorphin (inhibits dopamine release), (Tyrosine Hydroxylase activation –> more dopamine), and so much more.

D1 negative feedback cascade: ↑D1 → ↑adenylate cyclase → ↑cAMP → ↑CREB → (↑ΔFosB → ↑HDAC1 → ↓C-Fos → receptor desensitization), ↑dynorphin → dopamine release inhibition

D1 positive feedback cascade: ↑D1 → ↑adenylate cyclase → ↑cAMP → ↑CREB → (↑tyrosine hydoxylase → dopamine synthesis), neurogenesis, differentiation

Why “receptor density” is the wrong metric

Your idea of dopamine receptor upregulation may be wrong. So many things are said to “upregulate dopamine receptors”, but what does that truly mean? Well it’s not so simple. Usually receptor upregulation just hints at temporarily lowered neurotransmitter causing increased sensitivity to maintain homeostasis.

Cocaine upregulates dopamine receptors. But basically the transition of CREB to ΔFosB and Dynorphin, leading to a depletion of CREB and dopamine is evidence of tolerance to cocaine. So looking at receptors alone is SIMPLISTIC, especially when you consider the inhibitory role of D2 receptors which people here misconceive to be a good thing. It’s almost as simplistic as assuming Tyrosine Hydroxylase upregulation is why Bromantane is so great, which is one of many misconceptions I had in the past. It’s the mechanism that makes it great, not just downstream activity.

In order for a substance to be labeled a “dopamine upregulator”, its effects must persist after discontinuation.

Note on receptor density: G-protein-coupled receptors are composed of two binding regions: G proteins and β-arrestins. When β-arrestins are bound, receptors internalize (or downregulate). This leaves less receptors available for dopamine to bind to. Since D2 acts to inhibit unnecessary signaling, the result is combination of dyskinesia, psychosis and addiction.

The downsides of stimulants: addiction, tolerance and withdrawal

Psychostimulant addiction and withdrawal have a common point of interest: behavioral sensitization, or rather structural synaptic changes enhanced by the presence of dopamine itself. [66] This dopamine-reliant loop biasedly reinforces reward by making it more rewarding at the expense of other potential rewards, and this underlies hedonic drive. For example, stimulants stabilize attention in ADHD by making everything more rewarding. But as a consequence, learning is warped and addiction and dependence occurs. The consequences of hedonism are well illustrated by stimulant-induced behavioral sensitization: aberrant neurogenesis [16] [67] forming after a single dose of amphetamine but lasting at least a year in humans. [68]

Reliance on enkephalins: Behavioral sensitization (and by extension dopamine) is reliant on the opioid system. Excitatory direct medium spiny neurons (DMSNs) experience dendritic outgrowth, whereas inhibitory indirect medium spiny neurons (IMSNs) act reclusive in the presence of high dopamine. [70] DMSNs are dopamine receptor D1-containing, and IMSNs are D2-containing, although DMSNs in the nucleus accumbens (NAcc) contains both receptor types. Enkephalins prevent downregulation of the D1 receptor via RGS4, leading to preferential downregulation of D2. [65]

Relating back to ΔFosB, one interesting thing I found is that ΔFosB mediates dopamine desensitization through some dopaminergic drugs by recruiting Histone Deacetylase 1 to C-Fos thus decreasing its mRNA, and C-Fos is a transcription factor necessary for dopamine’s effects. C-Fos mediates neuronal plasticity, whereas ΔFosB decreases plasticity, so the loss of C-Fos means that the reward circuit for dopaminergics would become ingrained and resistant to updating. ΔFosB leads to CDK5 which upregulates D1 and downregulates inhibitory D2 receptors. This explains the upregulation of D1 from Cocaine, despite the withdrawal from other factors.

Upon drug cessation, the effects of dynorphin manifest acutely as dysphoria. Naturally dynorphin functions by programming reward disengagement and fear learning. It does this in part by inhibiting dopamine release, but anti-serotonergic mechanisms are also at play. [71]

Summary: Psychostimulant addiction requires both D1 [72] and the opioid system (due to enkephalin release downstream of D2 activation). Aberrant synaptogenesis occurs after single exposure to dopamine excess, but has long-lasting effects. Over time this manifests as dyskinesia, psychosis and addiction. Tolerance and withdrawal, in regards to stimulants, involves the reduction of dopamine receptor sensitivity, as well as the reduction of dopamine. The synaptogenic aspects of psychostimulants (behavioral sensitization) delay tolerance but it still occurs due to D2 downregulation and ΔFosB-induced dopamine receptor desensitization. Withdrawal encompasses the debt of tolerance, but it’s worsened by behavioral sensitization, as both memory-responsive reward and the formation of new hedonic circuitry is impaired. Dynorphin also acutely inhibits the release of dopamine, adding to the detriment.

Dopamine-induced neurotoxicity

Dopamine excess, if left unchecked, is both neurotoxic and debilitating.

Dopamine’s neurotoxic metabolite, DOPAL: Dopamine is degraded by monoamine oxidase (MAO) to form DOPAL, an “autotoxin” that is destructive to dopamine neurons. Decades ago this discovery led to MAO-B inhibitor Selegiline being employed for Parkinson’s treatment.

Enkephalin excess is potentially neurotoxic: A convincing theory (my own, actually) is that opioid receptor agonism is at least partially responsible for the neurotoxic effect of dopamine excess. Recently multiple selective MOR agonists were shown to be direct neurotoxins, most notably Oxycodone, [28] and this was partially reversed through opioid receptor antagonism, but fully reversed by ISRIB. In relation to stimulants, D2 activation releases enkephalins (scaling with the amount of dopamine), playing a huge role in addiction and behavioral sensitization. [29] Additionally, enkephalinergic neurons die after meth exposure due to higher dopamine [30] , which they attribute to dopamine quinone metabolites, but perhaps it is enkephalin itself causing this. Enkephalin is tied to the behavioral and neuronal deficits in Alzheimer’s [31] and oxidative stress [32] which signals apoptosis.

Antioxidants: Since oxidative stress is ultimately responsible for the neurotoxicity of dopamine excess, antioxidants have been used, with success, to reverse this phenomenon. [44] That being said, antioxidants inhibit PKC, [57] and PKCβII is required for dopamine efflux through the DAT. [55] This is why antioxidants such as NAC and others have been shown to blunt amphetamine. [56] TLR4 activation by inflammatory cytokines is also where methamphetamine gets some of its rewarding effects. [58]

What’s debunked as a dopamine strategy

See also What To Avoid.

Amphetamine (Adderall). Amphetamine receives praise across much of reddit, but perhaps it isn’t warranted. This isn’t to say that stimulants aren’t necessary. Their acute effects are very much proven. But here I question the long-term detriment of amphetamine. Beyond the wealth of anecdotes, both online and in literature, of prescription-dose amphetamine causing withdrawal, there exists studies conducted in non-human primates using amphetamine that show long-lasting axonal damage, withdrawal and schizotypal behavior from low dose amphetamine . This suggests a dopamine excess. These studies are the result of chronic use, but it disproves the notion that it is only occurs at high doses. Additionally, amphetamine impairs episodic memory [9] and slows the rate of learning ( Pemoline as well, but less-so) [10] in healthy people. This, among other things, completely invalidates use of amphetamine as a nootropic substance. [11]

Methylphenidate (Ritalin). Low-dose methylphenidate is less harmful than amphetamine, but since its relationship with dopamine is linear, [21] it may still be toxic at higher doses. It suppresses C-Fos, [20] but less-so [19] and only impairs cognition at high doses. [12] Neurotoxicity would manifest through inhibited dopamine axon proliferation, which in one study led to an adaptive decrease in dopamine transporters, after being given during adolescence. [13] Therefore I agree with the frequency at with Ritalin is prescribed over Adderall, however neither is completely optimal.

L-Tyrosine, L-Phenylalanine, DLPA, L-Dopa. I still believe L-Tyrosine, L-Phenylalanine and DLPA are useless for dopamine biosynthesis. Increased tyrosine concentrations beyond a healthy dietary intake does not result in much more dopamine under normal circumstances. [1] [2] TH is highly regulatory and is only activated as needed. [3] [4] Statistically, the American diet is sufficient in tyrosine, the amino acid found abundantly in meat alone. Supplementation with L-Tyrosine or L-Phenylalanine is only effective in a deficiency, and the likelihood of having one is slim. Excess of these amino acids can not only decrease dopamine, but produce oxidative stress. [14] Enkephalin inhibits Tyrosine Hydroxylase, and like I expressed in my former post, adding more of the building block means nothing if you don’t upregulate this enzyme. L-Dopa (Mucuna Pruriens in supplement form), come with many side effects, [15] so much so that it was unusable in older adults for the purpose of promoting cognition. In fact, it impaired learning and memory and mainly caused side effects. [16]

Uridine monophosphate/ triacetyluridine. A while back “Mr. Happy Stack” was said to upregulate dopamine receptors, and so many people took it envisioning improved motivation, better energy levels, etc. but that is not the case. Uridine works primarily through inhibiting the release of dopamine using a GABAergic mechanism, which increases dopamine receptor D2, an inhibitory dopamine receptor, and this potentiates antipsychotics. [59] [60] [61] Uridine is solidified as an antidopaminergic substance.

9-Me-BC (9-Methyl-β-carboline). Years after the introduction of this compound to the nootropics community, there is still no evidence it’s safe. Not even in rodent models. The debate about its proposed conversion to a neurotoxin is controversial, but the idea that it “upregulates dopamine” or “upregulates dopamine receptors” is not, nor is it founded on science. Its ability to inhibit MAO-A and MAO-B is most likely soley responsible for its dopaminergic effects. Additionally, I ran it through predictive analysis software, and it was flagged as a potential carcinogen on both ADMETlab and ProTox.

Selegiline. Selegiline is often misconceived as solely inhibiting the conversion of dopamine to DOPAL, which in an ideal scenario would simultaneously reduce neurotoxicity and raise dopamine. But more recent data shows Selegiline acting primarily a catecholamine release enhancer (CAE), and that BPAP (another CAE) extends lifespan even more. [22] This points to dopamine promoting longevity, not reduced DOPAL. Additionally, MAO-A was found to be responsible for the degradation of dopamine, not MAO-B, [23] thus suggesting an upregulation of tyrosine hydroxylase in dormant regions of the brain as Selegiline’s primary therapeutic mechanism in Parkinson’s. Tolerance forms to this effect, which is why patients ultimately resort to L-Dopa treatment. [25] Selegiline has been linked to withdrawal [26] but not addiction. [27] Given this, it would appear that the catecholaldehyde hypothesis lacks proof of concept.

How Bromantane upregulates dopamine and protects the brain

Full mechanism and dosing live on the Bromantane page. In short:

Bromantane is non-addictive, and as opposed to withdrawal, shows moderate dopaminergic effects even 1-2 months after its discontinuation. [34] [35] [37] It is not overly stimulating, [36] actually reduces anxiety, [37] reduces work errors, and improves physical endurance as well as learning. [38] [39] Its dopaminergic effects also improve sex-drive. [40]

Bromantane’s stimulatory effect is caused by increased dopamine synthesis, which it achieves through elevating CREB. [74] Dopamine blocks tyrosine hydroxylase, and CREB disinhibits this enzyme, leading to more dopamine being synthesized. Due to striking similarity (both chemically and pharmacologically), my hypothesis is that Bromantane, like Amantadine, is a Kir2.1 channel inhibitor. This stabilizes IMSNs in the presence of high dopamine and thus prevents aberrant synaptogenesis. Through immunosuppression, Amantadine alleviates inflammatory cytokines, leading to an indirect inhibition to HDAC that ultimately upregulates neurotrophins such as BDNF and GDNF. [76] Bromantane reduces inflammatory cytokines [75] and was shown to inhibit HDAC as well. [77] Literature suspects its sensitizing properties to be mediated through neurotrophins [78] and indeed the benefits of GDNF infusions in Parkinson’s last years after discontinuation. [79]

Summary: Bromantane increases dopamine synthesis, balances excitatory and inhibitory neural networks, and increases neurotrophins by reducing neuroinflammation through epigenetic mechanisms. Increased dopamine receptor density is not necessary for the upregulatory action of Bromantane.

How ALCAR upregulates dopamine and protects the brain

ALCAR (Acetyl-L-Carnitine) is a cholinergic, antioxidant, and neuroprotective drug shown to increase dopamine output long after discontinuation. [45] Additionally it is a clinically superior antidepressant in older populations, compared to SSRIs [46] and was shown to improve ADD, yet not ADHD, strangely. [48] It helps fatigue in Multiple Sclerosis better than Amantadine [47] pointing to it possibly helping CFS, and has a protective effect in early cognitive decline in Alzheimer’s patients. [49]

What both Bromantane and ALCAR have in common is their influence on HDAC. Instead of inhibiting HDAC, ALCAR donates an acetyl group to proteins deacetylated by HDAC1, which blocks the downregulatory effect of ΔFosB on C-Fos, promoting dopamine receptor sensitivity. Additionally this promotes GDNF [53] and these together could be how it upregulates dopamine output, or how it helps meth withdrawal. [52]

In relation to ΔFosB, ALCAR donates acetyl groups to deacetylated proteins which acts similar to a HDAC inhibitor (HDACI). ALCAR increases BDNF and therefore ERK1/2 (a slow transcription factor) and through that may enhance the sensitivity of D1. This upregulation of D1 activity leads to a continuation of PKA –> CREB activation and thus a positive feedback loop with DARPP-32, phosphorylating it at Thr34 over Thr75, when Thr75 phosphorylation inhibits PKA resulting in a tyrosine hydroxylase upregulation (?) and upregulated dopamine output long-term with no tolerance as ALCAR doesn’t activate ΔFosB or CDK5, and therefore upregulates D1 differently than cocaine.

ALCAR’s donation of an acetyl group to choline also makes it a potent cholinergic, and that combined with its antioxidant effects are likely responsible for its neuroprotection.

A later note from me. I have since retracted my recommendation of oral ALCAR over concerns about TMAO. The acetyl-donation mechanism above still stands, but the route of administration matters. See The Acetyl Story for the full update.

Salicin: a mild dopaminergic adjunct

Salicin is the active compound found in white willow bark extract, largely responsible for its anti-inflammatory effects.

When taken orally, 240mg Salicin can create salicylic acid mimicking 87mg of acetylsalicylic acid (aspirin), and unlike Aspirin, Salicin lacks side effects such as gastrointestinal damage and excessive blood thinning. White willow bark extract is largely considered to be safe and lacking in side effects.

Dopaminergic effects: Aspirin, at low doses, sufficiently stimulated CREB, causing rapid upregulation of tyrosine hydroxylase, and increased dopamine synthesis. Additionally, aspirin is found to prolong the dopaminergic effects of caffeine, by an incredible margin (from 2 hours, up to 6 in mice), showing a synergy between the compounds. Aspirin also reduces the level of dynorphin, which may be a contributing factor. Since CREB mediates the tyrosine hydroxylase upregulation, and this effect is also found with Salicin, it is likely to carry over.

Salicin itself appears to bind to novel bitter taste receptor expressed in the brain (TAS2Rs), which stimulates CREB. Despite these findings, there is not sufficient data to suggest that Aspirin, nor Salicin, produce a procognitive effect in healthy people. However, it can be safely assumed that Salicin has mild stimulatory and anti-inflammatory properties, and especially as an adjunct to caffeine and related compounds.

Conclusion

Dopamine is a vital neurotransmitter that can be increased for the benefit of many. Addiction, psychosis and dyskinesia are linked through synaptogenic malfunction, where the opioid system plays a key role. On the other hand, tolerance can be attributed to receptor desensitization and withdrawal involves receptor desensitization, synaptogenic malfunction and dynorphin. There have been many flawed strategies to increase dopamine, from Selegiline, dopamine precursors, Uridine Monophosphate, dopamine releasing agents and others, but the most underappreciated targets are neurotrophins such as GDNF. This is most likely why Bromantane and ALCAR have persistent benefits even long after discontinuation.

Key references

Sources

Write a comment